1. Pink Sheet
  2. >>Market Access

CVS Expands Formulary Exclusions In 2017, Express Scripts’ Tally Unchanged

 
• By Cathy Kelly

National formulary exclusions continue in 2017, with CVS aggressively expanding its list of “not covered” drugs. Express Scripts currently excludes slightly fewer drugs than last year but may still add to its list.

PS1607_FormularyCommitteePad_1200x675

CVS Health Corp. will exclude a total of 131 drugs from coverage under its standard national formulary in 2017 while Express Scripts Holding Co.’s national preferred formulary will exclude 85 drugs, according to recent announcements by the pharmacy benefit managers.

CVS and Express Scripts formularies each cover approximately 25 million individuals commercially insured through employers and health plans. The formulary...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Gene Therapy Elevidys Among Six Orphan Drugs Awaiting EU Marketing Verdict

 
• By Vibha Sharma

The European Medicines Agency is expected to decide whether to recommend EU-wide marketing authorization for six orphan-designated medicines that are all already approved in the US.

Business Background Of New CDER Director George Tidmarsh

 
• By Bridget Silverman

George Tidmarsh has extensive experience in the biopharmaceutical industry and led several drugs to FDA approval.

‘Prescription Drugs Are Not Golf Balls’: FTC/DoJ Solicit Clashing Opinions On Patents

 
• By Urtė Fultinavičiūtė

Innovator drug advocates argued that the number of patents asserted by industry is not too dissimilar to other fields. But should drugs be compared to golf balls?